Navigation Links
Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Date:3/25/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, March 25, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin* was recently submitted to the Food and Drug Administration (FDA) in the United States for the treatment of type 2 diabetes mellitus (T2D) in adults.

Empagliflozin is a member of the SGLT2 inhibitor class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

"We are excited to have submitted an application for a potential new treatment option that may help patients better manage their type 2 diabetes mellitus," said Christophe Arbet-Engels , MD, PhD, MBA, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim. "Type 2 diabetes mellitus is a critical health issue facing the world today, and through the Boehringer Ingelheim and Lilly Diabetes Alliance, we are committed to developing new treatments to address patients with this disease."

Empagliflozin is being investigated in adults with T2D in a Phase III clinical trial program that plans to enroll more than 14,500 patients.[1] In total, this program comprises 12 multinational clinical trials, including a large cardiovascular outcome trial. Boehringer Ingelheim and Lilly plan to present detailed data disclosures for many of these studies at scientific medical meetings and in publications in 2013 and 2014.

About Diabetes 
Approximately 25.8 million Americans[2] and an estimated 371 million people worldwide[3] have type 1 or ty
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
2. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
3. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
4. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
5. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
6. FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol for Maintenance Treatment of COPD
7. Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
8. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Boehringer Ingelheim Announces Equine Research Awards
11. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Oct. 19, 2014  Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, animal ... invested in Iwase Dental Supply, Inc., a leading full-service ... transaction marks Henry Schein,s entrance into Japan ... market, and increases to 28 the number of countries ...
(Date:10/17/2014)... , Oct. 17, 2014  Hanger, Inc. (NYSE: ... to report its results of operations for the quarter ... after the market closes.  A conference call to discuss ... ET, on Friday, November 7, 2014. Those wishing to ... until Friday, November 14, 2014 by dialing 1-855-859-2056 and ...
(Date:10/17/2014)... 17, 2014 According ... by Technique (Optical Coherence Tomography, Hyperspectral Imaging, ... (Ophthalmology, Neurology, Oncology, Cardiology) - Global Forecasts ... the Optical Imaging market over the forecast ... at $917.1 million in 2014 and is ...
Breaking Medicine Technology:Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4
... 2012 Mylan Pharmaceuticals ULC, the Canadian subsidiary ... today received approval from Health Canada for Mylan-Rosuvastatin ... is the generic version of Astra Zeneca,s Crestor® ... primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia.  According ...
... GROVE, Ill., March 15, 2012 For the ... (nail fungus), a new, fast, effective approach to ... leader in laser, light, radiofrequency and ultrasound aesthetic ... introduction of its newest innovation for the Harmony(XL) ...
Cached Medicine Technology:Mylan Canada Receives Health Canada Approval for Generic Version of Crestor® 2New Nail Fungus Approach Receives FDA Clearance 2
(Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
(Date:10/20/2014)... 20, 2014 JZ Fitness, an independently ... corporate wellness programming, authorship, international lecturing and community wellness, ... announce the release of the JZ Fitness nutrition app, ... of coaching thousands of individuals on nutrition, Jenn Zerling ... does not require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... October 20, 2014 Myoderm ... as Assistant Director of their CentralSource ... managing the innovative turnkey drug sourcing, distribution, and ... brings over 12 years of industry experience, in ... at the peak of their international success to ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2
... BioInformatics, LLC announces the pending release of its newest ... Products. As a result of the March 9, ... human embryonic stem cell research, suppliers of stem cell related ... new opportunities in the stem cell products market. In this ...
... Cookbook Hits Shelves April 28, 2009 ... in Twenty Episode, Half-Hour Series from Tiger Aspect Productions ... April 7 Do you want to have your cake ... Yourself Thin , an all-new series that offers viewers the ...
... responds to the publication of a long-secret report by International Committee ... in interrogations in CIA secret detention centers committed gross violations of ... ... Cambridge, MA (Vocus) April 7, 2009 -- The full ...
... Scope of Regulatory Practice, International StandardsROCKVILLE, Md., April ... Society (RAPS) has announced its newest Regulatory Affairs ... RAC (GS) credential denotes knowledge related to the ... the healthcare product sector, regardless of geographic location ...
... April 7 , ... Product Suite , Elsevier, ... information products and services, announced today the acquisition ... the provider of,Softwarefornurses.com online learning education products. PDS ...
... arthritis affects about 11 percent of patients with ... block signaling molecules that induce inflammation, improve the ... human monoclonal antibody that works against TNFα and ... weeks of the first subcutaneous injection in a ...
Cached Medicine News:Health News:BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products 2Health News:BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products 3Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 2Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 3Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 4Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 3Health News:RAPS Offers New International Regulatory Affairs Certification - RAC (GS) 2Health News:Elsevier Acquires Professional Development Software, Inc., Provider of 'Software for Nurses' Online Learning Education 2Health News:New drug shows promising results for psoriatic arthritis 2
The WADiana Compact is a fully automated immuno-haematology analyser, easy to use with maximum security including clot detection and ensuring no contamination....
The Ortho AutoVue System is an automated immunohematology testing system used for blood typing, antibody screening and compatibility testing using Ortho BioVue System cassettes....
ABS2000 is an automated system that can handle more workload. It allows accurate detection of antibodies that can be missed out by manual testing....
... vision and disposable lens convenience for those ... and want crisp, clear vision with the ... Toric. Vertex Toric lenses are manufactured using ... produces a perfect edge on every lens. ...
Medicine Products: